A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys

Journal of Virology

Volumn 78, Issue 18, 2004, Pages 9998-10008

  Guirakhoo, F ^a   Zhang, Z ^a   Myers, G ^a   Johnson, B W ^b   Pugachev, K ^a   Nichols, R ^a   Brown, N ^a   Levenbook, I ^c   Draper, K ^d   Cyrek, S ^d   Lang, J ^e   Fournier, C ^e   Barrere, B ^e   Delagrave, S ^f   Monath, T P ^a  

^a Acambis   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c Charles River Laboratories Inc ^*  (United States)

^d CHARLES RIVER LABORATORIES   (United States)

^e SANOFI PASTEUR   (France)

^f BioTech Studio LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; CHIMERIC YELLOW FEVER DENGUE 1 VACCINE; DENGUE VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE; YELLOW FEVER VACCINE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE; CHEMICAL BINDING; CHIMERA; CONTROLLED STUDY; DENGUE VIRUS; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HOST CELL; HUMAN; HUMAN CELL; MALE; MOLECULAR CLONING; MONKEY; MOSQUITO; MOUSE; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; VIREMIA; VIROGENESIS; VIRUS MUTATION; VIRUS STRAIN; VIRUS VIRULENCE; YELLOW FEVER FLAVIVIRUS;

AEDES; AMINO ACID SUBSTITUTION; ANIMALS; ANIMALS, SUCKLING; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; CHIMERA; DENGUE; DENGUE VIRUS; FEMALE; HUMANS; MACACA FASCICULARIS; MACACA MULATTA; MALE; MEMBRANE FUSION; MICE; MICE, INBRED ICR; MODELS, MOLECULAR; POINT MUTATION; VACCINES, ATTENUATED; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; VIREMIA; VIRULENCE; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 4444253499     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.18.9998-10008.2004     Document Type: Article

References (39)

1. Bhatt, T. R., M. B. Crabtree, F. Guirakhoo, T. P. Monath, and B. R. Miller. 2000. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14-14-2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am. J. Trop. Med. Hyg. 62:480-484.
2. Blaney, J. E., Jr., D. H. Johnson, G. G. Manipon, C. Y. Firestone, C. T. Hanson, B. R. Murphy, and S. S. Whitehead. 2002. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 300:125-139.
3. Burke, S., and T. P. Monath. 2001. Flaviviruses, p. 1049-1125. In D. M. Knipe et al. (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
4. Centers for Disease Control and Prevention. 2002. Adverse events associated with 17D-derived yellow fever vaccination-United States, 2001-2002. Morb. Mortal. Wkly. Rep. 51:989-993.
5. Durbin, A. P., R. A. Karron, W. Sun, D. W. Vaughn, M. J. Reynolds, J. R. Perreault, B. Thumar, R. Men, C. J. Lai, W. R. Elkins, R. M. Chanock, B. R. Murphy, and S. S. Whitehead. 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am. J. Trop. Med. Hyg. 65:405-413.
6. Edleman, R., S. S. Wasserman, S. A. Bodison, R. J. Putnak, K. H. Eckels, D. Tang, N. Kanesa-Thasan, D. W. Vaughn, B. L. Innis, and W. Sun. 2003. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am. J. Trop. Med. Hyg. 69:48-60.
7. Galler, R., K. V. Pugachev, C. L. Santos, S. W. Ocran, A. V. Jabor, S. G. Rodrigues, R. S. Marchevsky, M. S. Freire, L. F. Almeida, A. C. Cruz, A. M. Yamamura, I. M. Rocco, E. S. da Rosa, L. T. Souza, P. F. Vasconcelos, F. Guirakhoo, and T. P. Monath. 2001. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 290:309-319.
8. Guirakhoo, F., J. Arroyo, K. V. Pugachev, C. Miller, Z.-X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Soike, M. Ratterree, and T. P. Monath. 2001. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 75:7290-7304.
9. Guirakhoo, F., K. Pugachev, J. Arroyo, C. Miller, Z.-X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Draper, and T. P. Monath. 2002. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298:146-159.
10. Guirakhoo, F., K. Pugachev, Z. Zhang, G. Myers, I. Levenbook, K. Draper, J. Lang, S. Ocran, F. Mitchell, M. Parsons, N. Brown, S. Brandler, C. Fournier, B. Barrere, F. Rizvi, A. Travassos, R. Nichols, D. Trent, and T. Monath. 2004. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 78:4761-4775.
11. Guirakhoo, F., R. Weltzin, T. J. Chambers, Z.-X. Zhang, K. Soike, M. Ratterree, J. Arroyo, K. Georgakopoulos, J. Catalan, and T. P. Monath. 2000. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J. Virol. 74:5477-5485.
12. Guirakhoo, F., Z.-X. Zhang, T. J. Chambers, S. Delagrave, J. Arroyo, A. D. T. Barrett, and T. P. Monath. 1999. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257:363-372.
13. Halstead, S. B. 1988. Pathogenesis of dengue: challenges to molecular biology. Science 239:476-481.
14. Johnson, B. W., T. V. Chambers, M. B. Crabtree, F. Guirakhoo, T. P. Monath, and B. R. Miller. 2004. Analysis of the replication kinetics of the ChimeriVax-DEN 1,2,3,4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am. J. Trop. Med. Hyg. 70:89-97.
15. Johnson, B. W., T. V. Chambers, M. B. Crabtree, J. Arroyo, T. P. Monath, and B. R. Miller. 2003. Growth characteristics of the veterinary vaccine candidate ChimeriVax-West Nile (WN) virus in Aedes and Culex mosquitoes. Med. Vet. Entomol. 17:235-243.
16. Johnson, B. W., T. V. Chambers, M. B. Crabtree, T. R. Bhatt, F. Guirakhoo, T. P. Monath, and B. R. Miller. 2002. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes. Am. J. Trop. Med. Hyg. 67:260-265.
17. Kanesa-Thasan, N., R. Edelman, C. O. Tacket, S. S. Wasserman, D. W. Vaughn, T. S. Coster, G. J. Kim-Ahn, D. R. Dubois, J. R. Putnak, A. King, P. L. Summers, B. L. Innis, K. H. Eckels, and C. H. Hoke, Jr. 2003. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am. J. Trop. Med. Hyg. 69:17-23.
18. Kanesa-Thasan, N., W. Sun, G. Kim-Ahn, S. Van Albert, J. R. Putnak, A. King, B. Raengsakulsrach, H. Christ-Schmidt, K. Gilson, J. M. Zahradnik, D. W. Vaughn, B. L. Innis, J.-F. Saluzzo, and C. H. Hoke. 2001. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19:179-188.
19. Kliks, S. C., A. Nisalak, W. E. Brandt, L. Wahl, and D. S. Burke. 1989. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40:444-451.
20. Lee, E., R. C. Weir, and L. Dalgarno. 1997. Changes in the dengue virus major envelope protein on passaging and their localization on the three-dimensional structure of the protein. Virology 232:281-290.
21. Levenbook, I. S., L. J. Pelleu, and B. L. Elisberg. 1987. The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination. J. Biol. Stand. 15:305-313.
22. Marianneau, P., A. M. Steffan, C. Royer, M. T. Drouet, D. Jaeck, A. Kirn, and V. Deubel. 1999. Infection of primary cultures of human Kupffer cells by dengue virus: no viral progeny synthesis, but cytokine production is evident. J. Virol. 73:5201-5206.
23. Martin, M., L. H. Weld, T. F. Tsai, G. T. Mootrey, R. T. Chen, M. Niu, M. S. Cetron, and the GeoSentinel Yellow Fever Working Group. 2001. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg. Infect. Dis. 7:945-951.
24. Martin, M., T. F. Tsai, B. Cropp, G.-J. J. Chang, D. A. Holmes, J. Tseng, W.-J. Shieh, S. R. Zaki, I. Al-Sanouri, A. F. Cutrona, G. Ray, L. H. Weld, and M. S. Cetron. 2001. Fever and multisystem organ failure associated with 17D-204 yellow fever: a report of four cases. Lancet 358:98-104.
25. Modis, Y., S. Ogata, D. Clements, and S. C. Harrison. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. USA 100:6986-6991.
26. Monath, T. P., and A. D. Barrett. 2003. Pathogenesis and pathophysiology of yellow fever. Adv. Virus Res. 60:343-395.
27. Monath, T. P. 2004. Yellow fever vaccine, p. 1095-1176. In S. Plotkin and W. Orenstein (ed.), Vaccine, 4th ed. Saunders, Philadelphia, Pa.
28. Monath, T. P., I. Levenbook, K. Soike, Z.-X. Zhang, M. Ratterree, K. Draper, A. D. T. Barrett, R. Nichols, R. Weltzin, J. Arroyo, and F. Guirakhoo. 2000. Chimeric yellow fever 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J. Virol. 74:1742-1751.
29. Monath, T. P., J. Arroyo, I. Levenbook, Z.-X. Zhang, J. Catalan, K. Draper, and F. Guirakhoo. 2002. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J. Virol. 76:1932-1943.
30. National Institutes of Health. 1998. Guide for the care and use of laboratory animals, revised ed. Department of Health and Human Services publication no. (NIH) 85-23. National Institutes of Health, Bethesda, Md.
31. Pugachev, K. V., F. Guirakhoo, S. W. Ocran, F. Mitchell, M. Parsons, C. Penal, S. Girakhoo, S. O. Pougatcheva, J. Arroyo, D. W. Trent, and T. P. Monath. 2004. High fidelity of yellow fever virus RNA polymerase. J. Virol. 78:1032-1038.
32. Rigau-Pérez, J. G., G. G. Clark, D. J. Gubler, P. Reiter, E. J. Sanders, and A. V. Vorndam. 1998. Dengue and dengue haemorrhagic fever. Lancet 352:971-977.
33. Sabchareon, A., J. Lang, P. Chanthavanich, S. Yoksan, R. Forrat, P. Attanath, C. Sirivichayakui, K. Pengsaa, C. Pojjaroen-Anat, W. Chokejindachai, A. Jagsudee, J.-F. Saluzzo, and N. Bhamarapravati. 2002. Safety and immunogenicity of tetravalent live-attenuated dengue vaccine in Thai adult volunteers: role of serotype concentration, ratio and multiple doses. Am. J. Trop. Med. Hyg. 66:264-272.
34. Saluzzo, J. F. 2003. Empirically derived live-attenuated vaccines against dengue and Japanese encephalitis. Adv. Virus Res. 61:419-443.
35. Sun, W., R. Edelman, N. Kanesa-Thasan, K. H. Eckels, J. R. Putnak, A. D. King, H. S. Houng, D. Tang, J. M. Scherer, C. H. Hoke, Jr., and B. L. Innis. 2003. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am. J. Trop. Med. Hyg. 69:24-31.
36. Vasconcelos, P. F. C., E. J. Luna, R. Galler, L. Silva, T. L. Coimbra, V. R. L. S. Barros, T. P. Monath, S. G. Rodrigues, C. Laval, Z. G. Cosata, M. F. G. Vilela, C. L. S. Santos, C. M. O. Papaiordanou, V. A. F. Alves, L. D. Andrade, H. K. Sato, E. S. T. Rosa, G. B. Froguas, E. Lacava, L. M. R. Almeida, A. C. R. Cruz, I. M. Rocco, R. T. M. Santos, and O. F. P. Oliva. 2001. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 358:91-97.
37. World Health Organization. 1988. Annex 9. Requirements for yellow fever vaccine. Addendum 1987. W.H.O. Tech. Rep. Ser. no. 771:208. World Health Organization, Geneva, Switzerland.
38. World Health Organization. 1998. Requirements for yellow fever vaccine (requirements for biological substances no. 3.) W.H.O. Expert Committee on Biological Standardization, 46th report. W.H.O. Tech. Rep. Ser. 872. W.H.O. fact sheet no. 117, revised April 2002. World Health Organization, Geneva, Switzerland.
39. World Health Organization. 2002. W.H.O. fact sheet no. 117. World Health Organization, Geneva, Switzerland.